Does Humana Cover Ozempic for Weight Loss? The 2026 Plan-by-Plan Answer

Direct answer (40-60 words)

Humana almost never covers Ozempic for weight loss. Ozempic is FDA-approved for type 2 diabetes only, so Humana plans treat weight-loss prescriptions as off-label and deny them. Wegovy (the same molecule, FDA-approved for weight loss) has a better chance under plans with anti-obesity benefits, but prior authorization is required and denial rates are high.

Table of contents

1. The 30-second answer
2. Why Ozempic gets denied for weight loss across Humana plans
3. On-label vs off-label: the rule that drives every coverage decision
4. Coverage by Humana plan type (employer, ACA, Medicare, Medicaid)
5. Wegovy coverage: where Humana members have a real shot
6. The prior authorization process and what makes denials common
7. What to do if Humana denies your claim
8. The compounded semaglutide cash alternative
9. How to verify your specific Humana coverage in 10 minutes
10. FAQ
11. Footer disclaimers

Why Ozempic gets denied for weight loss across Humana plans

The denial isn't personal and it isn't your provider's fault. Humana's pharmacy benefit manager runs a coded check at the pharmacy counter: prescription drug code plus diagnosis code. Ozempic's drug code is paired with covered diagnoses (type 2 diabetes) in the formulary. Any other diagnosis code triggers an automatic denial.

For weight-loss prescriptions, the diagnosis is usually one of:

• E66.01 (morbid obesity)
• E66.9 (obesity, unspecified)
• Z71.3 (dietary counseling and surveillance)

None of these are on Ozempic's covered diagnosis list at Humana. The claim rejects in seconds and the patient sees a $940+ cash price at the pharmacy counter.

This is the same pattern across Aetna, Cigna, UnitedHealthcare, and almost every major U.S. insurer. Humana isn't unusually strict here. The system is built to deny off-label use of expensive medications.

On-label vs off-label: the rule that drives every coverage decision

A drug's FDA approval is for a specific condition at a specific dose. Insurers build their formularies around those approvals. When a doctor prescribes a medication for an unapproved condition (off-label use), it's legal and clinically common, but insurers can refuse to pay.

Ozempic's FDA approvals:

• Type 2 diabetes management (2017)
• Reducing cardiovascular event risk in adults with type 2 diabetes and known heart disease (2020)

Ozempic is not FDA-approved for chronic weight management. Wegovy is. They contain the same molecule (semaglutide) at slightly different maximum doses (Ozempic up to 2 mg, Wegovy up to 2.4 mg), but Novo Nordisk markets them as different products specifically because of this approval distinction.

For Humana coverage purposes, this matters more than the chemistry:

Drug	FDA-approved for	Humana coverage probability for weight loss
Ozempic	Type 2 diabetes	Near zero
Wegovy	Chronic weight management	Possible, plan-dependent, with prior auth
Mounjaro	Type 2 diabetes	Near zero for weight loss
Zepbound	Chronic weight management	Possible, plan-dependent, with prior auth
Rybelsus (oral semaglutide)	Type 2 diabetes	Near zero for weight loss

The shortcut: if the FDA approval is for diabetes, no insurer covers it for weight loss. If the FDA approval is for weight loss, you're back in the running, but the bar is still high.

Coverage by Humana plan type

Humana isn't one plan. It's a family of products with different rules.

Employer-sponsored commercial plans.

These show the most variability. Coverage depends on the employer's choices when designing the benefit. Some Fortune 500 employers add anti-obesity medication coverage to keep their employees competitive in a job market that increasingly expects it. Others exclude weight-loss drugs entirely to control pharmacy spend.

The first thing to do is pull your plan's formulary (the official drug coverage list). Search for "semaglutide" and "tirzepatide." If they're listed with a tier number, you have potential coverage. If they're absent or marked "excluded," coverage doesn't exist for this plan year.

Roughly 30 to 40% of large employer plans included weight-loss medication coverage in 2024 per the Mercer National Survey of Employer-Sponsored Health Plans. The rest didn't.

ACA marketplace plans.

ACA silver, gold, and platinum plans set their own formularies. Most don't cover Ozempic or Wegovy for weight loss. A small minority of state-specific plans cover Wegovy with strict prior authorization criteria.

If you're shopping for a marketplace plan and weight-loss medication coverage matters to you, the formulary is publicly available before enrollment. Check before you sign up rather than after.

Medicare Advantage and Part D.

Medicare law has historically excluded weight-loss medications. The Medicare Modernization Act of 2003 explicitly carved them out of Part D. Recent reform proposals (the Treat and Reduce Obesity Act) would change this, but as of 2026 the law hasn't changed.

What this means in practice: Humana Medicare Advantage and Part D plans cover Ozempic for type 2 diabetes only. Wegovy isn't covered for weight loss under any standard Medicare benefit. The exception is Wegovy's 2024 cardiovascular indication for patients with established heart disease and overweight/obesity, which Medicare has begun covering on a case-by-case basis under prior authorization.

Medicaid (Humana CareSource and similar).

Medicaid coverage varies by state. Some states (California, Pennsylvania, Virginia) cover Wegovy with prior authorization. Others don't cover any weight-loss medication. Humana's Medicaid managed care plans follow the state's underlying Medicaid formulary.

Wegovy coverage: where Humana members have a real shot

If your Humana plan covers anti-obesity medications, Wegovy is the right prescription to ask for, not Ozempic. Wegovy is on-label for weight loss and your provider can submit a clean prior authorization.

Typical Humana prior authorization criteria for Wegovy:

• BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Documented attempt at supervised weight loss through diet and exercise for 3 to 6 months prior to medication request
• Current participation in a behavioral or lifestyle intervention program
• Patient over age 18 (some plans require over 12 with adolescent-specific criteria)
• No contraindications (personal or family history of medullary thyroid carcinoma or MEN 2 syndrome)

The documentation requirement is real. Many denials happen not because the patient doesn't qualify but because the supervised weight-loss attempt isn't documented in the clinical record. If your provider plans to submit a Wegovy prior authorization, ask them to document your weight-loss history (diet attempts, exercise programs, prior medications, weight trends) in detail at the visit before submission.

Approval timelines run 3 to 14 days for clean submissions and 2 to 6 weeks for ones that require additional documentation. Once approved, prior authorizations typically last 6 to 12 months before reauthorization is needed.

The prior authorization process and what makes denials common

The PA process at Humana looks like this:

1. Provider submits the PA form with diagnosis codes, BMI, comorbidities, and prior weight-loss attempts.
2. Humana's pharmacy benefit manager reviews against criteria.
3. Decision returns in 3 to 14 days for standard requests, 24 to 72 hours for urgent requests.
4. Approved: prescription fills with copay or coinsurance.
5. Denied: patient and provider receive denial letter with appeal rights.

Common denial reasons:

• Insufficient documentation of supervised weight-loss attempts. This is the most frequent. "Patient has tried to lose weight" isn't enough. Specific diet programs, dates, and weight changes need to be in the record.
• BMI just below threshold. A patient at BMI 26.8 with hypertension is below the cutoff. Sometimes weight changes during the documentation period push the BMI down, then the PA denies.
• Missing comorbidity documentation. A patient with sleep apnea may not have a current sleep study on file. The diagnosis needs to be active and recent in the chart.
• Wrong drug requested. A weight-loss prior auth for Ozempic almost always denies. The same patient might get Wegovy approved.
• Missing behavioral program documentation. Some plans require concurrent enrollment in a structured lifestyle program. A simple "I exercise and watch what I eat" doesn't qualify.

A clean resubmission after fixing documentation gaps has a meaningfully higher approval rate than an appeal of a flat denial. If the first PA denies for documentation reasons, ask your provider to fix and resubmit rather than appeal.

What to do if Humana denies your claim

Three paths exist after a denial.

Path 1: Appeal.

You and your provider have the right to appeal a denial. Standard appeals take 30 to 60 days. Expedited appeals (when delay would jeopardize health) take 72 hours. Success rates for appeals are low when the underlying issue is off-label use of Ozempic, and modest (around 30 to 40%) when the issue is documentation of a denied Wegovy PA.

Appeals work best when:

• New clinical information is included
• The denial reason is clearly procedural rather than substantive
• Your provider writes a detailed letter of medical necessity

Path 2: Switch to a covered alternative.

Some patients have luck with phentermine, topiramate, or naltrexone-bupropion (Contrave), all of which are FDA-approved for weight loss and more commonly covered by Humana than GLP-1 medications. These work through different mechanisms and have different side-effect profiles. They're not as effective as semaglutide or tirzepatide, but they're meaningfully cheaper and easier to get covered.

Phentermine alone, generic, runs $10 to $30 per month with most insurance copays.

Path 3: Move to cash-pay compounded semaglutide.

For patients with no realistic path to insurance coverage, compounded semaglutide through a state-licensed compounding pharmacy costs $179 to $279 per month (FormBlends pricing) versus $1,000 to $1,300+ per month for cash-pay brand-name Ozempic.

This is the path most patients without strong insurance coverage end up on. The trade-offs are real (compounded semaglutide is not FDA-approved, comes in a vial drawn with an insulin syringe rather than a pre-filled pen, and requires a working understanding of dosing), but the cost is sustainable and the underlying molecule is identical.

The compounded semaglutide cash alternative

Compounded semaglutide is prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. The pharmacy obtains pharmaceutical-grade semaglutide API and prepares it according to the prescription, often combining it with B12 or other additives.

Key facts:

• Compounded semaglutide is not FDA-approved.
• It contains the same active molecule as Ozempic and Wegovy.
• It's prepared per individual patient prescription, not mass-manufactured.
• It's drawn from a vial with a U-100 insulin syringe rather than delivered by a pre-filled pen.
• It's not interchangeable with brand-name semaglutide products under FDA rules.

Pricing through telehealth platforms like FormBlends typically falls between $179 and $279 per month, including the medical visit, prescription, pharmacy fulfillment, and supplies. Pricing through local compounding pharmacies varies more but generally lands in a similar range.

For patients with insurance that covers Wegovy at a low copay, the brand-name path makes more sense. For patients who would otherwise pay $1,000+ monthly cash, the compounded path is the option that makes treatment financially possible.

How to verify your specific Humana coverage in 10 minutes

Step 1: Log into your Humana member portal.

Most members have an online account at humana.com. The plan documents section includes your formulary (drug coverage list).

Step 2: Search the formulary for "semaglutide" and "Wegovy."

You're looking for tier placement and any restriction notes (PA = prior authorization required, ST = step therapy, QL = quantity limit). If "semaglutide" appears with a tier number, your plan has potential coverage.

Step 3: Check if Ozempic is listed for diabetes coverage.

If you have a type 2 diabetes diagnosis, Ozempic is almost certainly on the formulary at Tier 2 or 3. Coverage at this tier means a $30 to $200 monthly copay for diabetes patients.

Step 4: Call Humana member services.

The number is on your insurance card. Ask the representative two questions: "Is Ozempic on the formulary for weight loss?" and "Is Wegovy on the formulary, and what are the prior authorization requirements?" The answers usually take 5 to 10 minutes.

Step 5: If covered, schedule the provider visit.

Bring your weight-loss history, current weight, and a list of any comorbidities. The provider needs this for the PA submission. The more documentation you bring to the visit, the faster the PA process moves.

This 10-minute exercise saves weeks of back-and-forth between provider, pharmacy, and insurer.

FAQ

Does Humana cover Ozempic for weight loss?

Almost never. Ozempic is FDA-approved for type 2 diabetes, not weight loss. Humana plans treat weight-loss prescriptions for Ozempic as off-label and deny them.

Does Humana cover Wegovy?

Some Humana plans cover Wegovy with prior authorization. Coverage depends on whether your specific plan includes anti-obesity medication benefits. Pull your plan's formulary to check.

Does Humana Medicare cover Ozempic for weight loss?

No. Medicare law excludes weight-loss medications from Part D coverage, and Humana Medicare Advantage plans follow this rule. Ozempic is covered for type 2 diabetes only.

Will Humana cover Ozempic if I have prediabetes?

Probably not. Ozempic's FDA approval is for type 2 diabetes specifically. Most Humana plans require an active type 2 diabetes diagnosis (ICD-10 codes E11.x) for Ozempic coverage. Prediabetes (R73.03) usually doesn't qualify.

How much does Ozempic cost without Humana coverage?

Cash price runs $940 to $1,300 per month for any Ozempic dose. The Novo Nordisk savings card can bring this to $25 per fill for commercially insured patients with type 2 diabetes, but doesn't apply to Medicare patients or off-label weight-loss use.

What is prior authorization and why does Humana require it for Wegovy?

Prior authorization is documentation that proves medical necessity before the insurer approves coverage. Humana uses it for expensive medications to limit access to patients who meet specific criteria (BMI threshold, comorbidities, prior weight-loss attempts). It's a cost-control measure.

How long does Humana prior authorization take?

Standard PA requests take 3 to 14 days. Expedited requests (when delay would risk health) take 24 to 72 hours. Documentation gaps can extend the timeline by 2 to 6 weeks.

What if my Humana PA for Wegovy is denied?

You and your provider can appeal, fix documentation gaps and resubmit, switch to a different covered weight-loss medication, or move to cash-pay compounded semaglutide. The right path depends on the denial reason.

Can I use my Humana HSA or FSA to pay for compounded semaglutide?

Yes, typically. Medically supervised weight-loss programs with prescription medications usually qualify as eligible HSA/FSA expenses. Confirm with your administrator.

Why is Wegovy covered but Ozempic isn't covered for weight loss?

Wegovy has FDA approval for chronic weight management. Ozempic doesn't. Insurance coverage follows FDA approval, so the same molecule (semaglutide) is covered in one form and not the other when the prescription is for weight loss.

Does Humana cover Zepbound or Mounjaro for weight loss?

Same logic as semaglutide: Zepbound is FDA-approved for weight loss and may be covered with prior authorization. Mounjaro is FDA-approved for type 2 diabetes only and is rarely covered for weight loss.

Is compounded semaglutide cheaper than going through Humana?

For patients without weight-loss medication coverage, yes. Compounded semaglutide at $179 to $279 per month is far cheaper than $1,000+ cash-pay Ozempic. For patients with strong insurance coverage and low Wegovy copays, brand-name Wegovy may still be the better deal.

Author / review note

Reviewed by the FormBlends Medical Team. References include the Centers for Medicare & Medicaid Services Part D guidance, the 2024 Mercer National Survey of Employer-Sponsored Health Plans, the Novo Nordisk Ozempic and Wegovy prescribing information, and the Treat and Reduce Obesity Act legislative history.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Humana is a registered trademark of Humana Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.